Novo Nordisk’s recent Alzheimer’s trials involving GLP-1 drugs were unsuccessful, yet scientists remain optimistic about their potential preventive application. Despite failing targets, the trials of semaglutide, a component in Ozempic and Wegovy, have prompted further research contemplation among experts.
